Latest Conference Articles

June 3rd 2012, 5:26am

ASCO Annual Meeting

Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.

June 3rd 2012, 5:00am

ASCO Annual Meeting

Patients with metastatic, hormone-sensitive prostate cancer and minimal disease spread experience a two-year boost in median survival when treated with continuous, rather than intermittent, hormonal therapy.

June 2nd 2012, 2:19pm

ASCO Annual Meeting

Dr. Eric Pujade-Lauraine, from Université de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.

June 2nd 2012, 9:09am

ASCO Annual Meeting

Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558

June 2nd 2012, 6:27am

ASCO Annual Meeting

Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.

June 2nd 2012, 6:21am

ASCO Annual Meeting

Study finds that more than two-thirds of patients with metastatic kidney cancer prefer pazopanib over another FDA-approved treatment, sunitinib.

June 2nd 2012, 5:59am

ASCO Annual Meeting

Adolescent and young adult patients between the ages of 16 and 30 had poorer outcomes when given the same treatment regimen as younger acute lymphoblastic leukemia patients.

June 2nd 2012, 5:39am

ASCO Annual Meeting

An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.

June 1st 2012, 4:01pm

ASCO Annual Meeting

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on Dabrafenib and Trametinib Combination Side Effects

June 1st 2012, 5:00am

ASCO Annual Meeting

Pharmaceutical industry analysts and companies have been weighing in on their selections for the most noteworthy research to be presented during the 2012 ASCO Annual Meeting.

May 31st 2012, 2:10pm

ASCO Annual Meeting

American Society of Clinical Oncology (ASCO) 2012 Annual Meeting video highlights, from OncLive TV.

May 30th 2012, 1:51pm

ASCO Annual Meeting

On May 16, the ASCO highlighted the results of five ground-breaking studies in advance of its annual meeting held in Chicago from June 1-5, 2012.

May 30th 2012, 12:40pm

ASCO Annual Meeting

Dr. Andre Goy, from John Theurer Cancer Center, Highlights Research From the 2012 ASCO Meeting.

May 30th 2012, 10:06am

ASCO Annual Meeting

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on the Unique Attributes of Neoadjuvant Zytiga.

May 29th 2012, 12:09pm

AACE Annual Scientific and Clinical Congress

Dr. Paul W. Ladenson, from Johns Hopkins Medicine, on Diagnosis of Thyroid Nodules

May 29th 2012, 6:42am

AACE Annual Scientific and Clinical Congress

Results of a multi-generational case study strengthen the case for genetic screening in cases of hereditary thyroid cancer.

May 29th 2012, 6:38am

AACE Annual Scientific and Clinical Congress

Patients are more likely to present with regional or distant metastases and experience lower rates of cancer-free survival depending on where they live.

May 29th 2012, 6:28am

AACE Annual Scientific and Clinical Congress

Researchers find that overexpression of a specific gene is associated with poor survival in patients with adrenocortical carcinoma.

May 25th 2012, 9:33am

AACE Annual Scientific and Clinical Congress

Another presentation at the AACE meeting on Thursday featured Dr. Saleh Aldasouqi, FACE, ECNU, discussing a topic that is not heard about too often in the medical world: tattoos.

May 24th 2012, 1:21pm

AACE Annual Scientific and Clinical Congress

Patients who live far from medical facilities benefit from having "virtual" conversations with their doctors and are comfortable with that arrangement.